BioLineRx (BLRX)
(Delayed Data from NSDQ)
$0.57 USD
0.00 (-0.02%)
Updated Jun 28, 2024 03:56 PM ET
After-Market: $0.57 0.00 (0.02%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
BioLineRx Ltd. [BLRX]
Reports for Purchase
Showing records 181 - 200 ( 204 total )
Company: BioLineRx Ltd.
Industry: Medical - Drugs
Company: BioLineRx Ltd.
Industry: Medical - Drugs
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: BioLineRx Ltd.
Industry: Medical - Drugs
Company: BioLineRx Ltd.
Industry: Medical - Drugs
1Q13 Highlights Movement Across the Portfolio
Provider: Roth Capital Partners, Inc.
Analyst: HAZLETT R
Company: BioLineRx Ltd.
Industry: Medical - Drugs
Company: BioLineRx Ltd.
Industry: Medical - Drugs
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: BioLineRx Ltd.
Industry: Medical - Drugs
Company: BioLineRx Ltd.
Industry: Medical - Drugs
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: BioLineRx Ltd.
Industry: Medical - Drugs
Company: BioLineRx Ltd.
Industry: Medical - Drugs
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: BioLineRx Ltd.
Industry: Medical - Drugs
Company: BioLineRx Ltd.
Industry: Medical - Drugs
Company: BioLineRx Ltd.
Industry: Medical - Drugs
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: BioLineRx Ltd.
Industry: Medical - Drugs
Company: BioLineRx Ltd.
Industry: Medical - Drugs
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: BioLineRx Ltd.
Industry: Medical - Drugs
Company: BioLineRx Ltd.
Industry: Medical - Drugs
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: BioLineRx Ltd.
Industry: Medical - Drugs
Licenses An Oncologic and Decent Ciliac Disease Data
Provider: Roth Capital Partners, Inc.
Analyst: HAZLETT R
Company: BioLineRx Ltd.
Industry: Medical - Drugs
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.